SpringWorks Therapeutics (SWTX) Revenue & Revenue Breakdown
SpringWorks Therapeutics Revenue Highlights
Latest Revenue (Y)
$5.45M
Latest Revenue (Q)
$21.01M
SpringWorks Therapeutics Revenue by Period
SpringWorks Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $5.45M | -11.39% |
| 2022-12-31 | $6.15M | 100.00% |
| 2021-12-31 | - | -100.00% |
| 2020-12-31 | $35.00M | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | - |
SpringWorks Therapeutics generated $5.45M in revenue during NA 2023, up -11.39% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
SpringWorks Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $21.01M | 285.64% |
| 2023-12-31 | $5.45M | -2.49% |
| 2023-09-30 | $5.59M | -4.15% |
| 2023-06-30 | $5.83M | 4.88% |
| 2023-03-31 | $5.56M | -4.17% |
| 2022-12-31 | $5.80M | 592.00% |
| 2022-09-30 | $838.00K | 140.80% |
| 2022-06-30 | $348.00K | 6860.00% |
| 2022-03-31 | $5.00K | 100.00% |
| 2021-12-31 | - | -100.00% |
| 2021-09-30 | $121.00K | -28.82% |
| 2021-06-30 | $170.00K | -26.09% |
| 2021-03-31 | $230.00K | -99.34% |
| 2020-12-31 | $35.00M | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | - |
SpringWorks Therapeutics generated $21.01M in revenue during Q1 2024, up 285.64% compared to the previous quarter, and up 362.23% compared to the same period a year ago.
SpringWorks Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| AMLX | Amylyx Pharmaceuticals | $380.79M | $88.64M |
| APLS | Apellis Pharmaceuticals | $366.28M | $179.14M |
| BPMC | Blueprint Medicines | $249.38M | $138.16M |
| KYMR | Kymera Therapeutics | $78.59M | $10.29M |
| ARVN | Arvinas | $78.50M | $76.50M |
| RLAY | Relay Therapeutics | $25.55M | - |
| RVMD | Revolution Medicines, Inc. Warrant | $11.58M | - |
| RNA | Avidity Biosciences | $9.56M | $2.04M |
| STOK | Stoke Therapeutics | $8.78M | $4.22M |
| SWTX | SpringWorks Therapeutics | $5.45M | $21.01M |
| PLRX | Pliant Therapeutics | $1.58M | - |
| BCEL | Atreca | $770.00K | $80.00K |
| BDTX | Black Diamond Therapeutics | - | - |
| DAWN | Day One Biopharmaceuticals | - | $8.19M |
| CERE | Cerevel Therapeutics | - | - |
| PASG | Passage Bio | - | - |
| TERN | Terns Pharmaceuticals | - | - |
| SANA | Sana Bio | - | - |
| GLUE | Monte Rosa Therapeutics | - | $4.70M |
SWTX Revenue FAQ
What is SpringWorks Therapeutics’s yearly revenue?
SpringWorks Therapeutics's yearly revenue for 2023 was $5.45M, representing a decrease of -11.39% compared to 2022. The company's yearly revenue for 2022 was $6.15M, representing an increase of 100.00% compared to 2021. SWTX's yearly revenue for 2021 was $0, representing a decrease of -100.00% compared to 2020.
What is SpringWorks Therapeutics’s quarterly revenue?
SpringWorks Therapeutics's quarterly revenue for Q1 2024 was $21.01M, a 285.64% increase from the previous quarter (Q4 2023), and a 278.01% increase year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $5.45M, a -2.49% decrease from the previous quarter (Q3 2023), and a -6.07% decrease year-over-year (Q4 2022). SWTX's quarterly revenue for Q3 2023 was $5.59M, a -4.15% decrease from the previous quarter (Q2 2023), and a 566.59% increase year-over-year (Q3 2022).
What is SpringWorks Therapeutics’s revenue growth rate?
SpringWorks Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was 0%.